Pathogenesis of heart failure. Changing conceptual paradigms

Acta Cardiologica

Volumn 53, Issue 3, 1998, Pages 131-141

  De Keulenaer, Gilles W ^a   Brutsaert, Dirk L ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cytokines; Endocardium; Endothelin; Endothelium; Heart failure; TNF

Indexed keywords

CYTOKINE; NEUROHORMONE;

ENDOTHELIUM CELL; HEART FAILURE; NEUROENDOCRINE DISEASE; PATHOGENESIS; REVIEW; SYNDROME;

ANIMALS; CYTOKINES; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; RECEPTORS, ENDOTHELIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0031756132     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Bourassa MG, Gurné O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, Johnstone DE, Yusuf S. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993; 2 (suppl A): 14A-19A.
2. Ventura HO, Murgo JP, Smart FW, Stapleton DD, Price HL. Current issues in advanced heart failure. Med Clin N Am 1992; 76: 1057-1082.
3. Gheorgiade M, Bonow RO. Chronic heart failure in the United States. A manifestation of coronary artery disease. Circulation 1998; 97: 282-289.
4. Brutsaert DL, Sys SU. Diastolic dysfunction in heart failure. J Card Failure 1997; 3: 225-242.
5. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiological and therapeutic implications. J Am Coll Cardiol 1993; 22: 318-325.
6. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GR, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547-1552.
7. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
8. Cody RJ. Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. J Am Coll Cardiol 1993; 22 (suppl A): 165A-167A.
9. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zelpis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-1475.
10. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
11. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
12. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
13. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
14. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-667.
15. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
16. Køber L, Torp-Pedersen-C, Carlsen JE, Bagger H, Eliasen P, Lyngborg V, Videbæk J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-1676.
17. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-254.
18. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CF, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND study (Trial on Reversing Endothelial Dysfunction). Circulation 1996; 94: 258-265.
19. Brutsaert DL. The endocardium. An Rev Physiol 1989; 51: 263-273.
20. Brutsaert DL, Meulemans AL, Sipido KR, Sys SU. Endocardial control of myocardial performance. In: Sugi H, Pollack GH, eds. Molecular Mechanism of Muscle Contraction. Proceedings of the 1986 Muscle Symposium, Hakone, Japan. Plenum, New York, 1986: 609-616.
21. Brutsaert DL, Meulemans AL, Sipido KR, Sys SU. Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle. Circ Res 1988: 62: 358-366.
22. Li K, Rouleau JL, Andries LJ, Brutsaert DL. Effect of dysfunctional vascular endothelium on myocardial performance in isolated papillary muscles. Circ Res 1993; 72: 768-777.
23. Brutsaert DL. Role of endocardium in cardiac overloading and failure. European Heart Journal 1990; 11 (suppl G): 8-16.
24. Brutsaert DL, Andries LJ. The endocardial endothelium. Am J Physiol 1992; 263: H985-1002.
25. Andries LJ, Kaluza G, De Keulenaer GW, Mebazaa A, Brutsaert DL, Sys SU. Endocardial endothelial dysfunction and heart failure. J Card Failure 1996; 2 (4 suppl): S195-202.
26. Mebazaa A, De Keulenaer GW, Paqueron X, Andries LJ, Brutsaert DL, Sys SU. Cardiac endothelial activation in endotoxin-cardiomyopathy (submitted).
27. Qi X-L, Stewart D, Gosselin H, Arad A, Andries LJ, Sys SU, Brutsaert DL, Rouleau JL. The improved effect of endocardial and vascular endothelial function on myocardial performance by captopril in postinfarct rat hearts (submitted).
28. Treasure BC, Alexander RW. The dysfunctional endothelium in heart failure. J Am Coll Cardiol 1993; 22 (suppl A): 129-A-134A.
29. Drexler H, Hornig B. Importance of endothelial function in chronic heart failure. J Cardiov Pharmacol 1996; 72 (suppl 2): S9-S12.
30. Schaufelberger M, Andersson G, Eriksson BO, Grimby G, Held P, Swedberg K. Skeletal muscle changes in patients with chronic heart failure before and after treatment with enalapril. Eur Heart J 1996; 17: 1678-1685.
31. Opasich C, Aquilani R, Dossena M, Foppa P, Catapano M, Pagani S, Pasini E, Ferrari R, Tavazzi L, Pastoris O. Biochemical analysis of muscle biopsy in overnight fasting patients with severe chronic heart failure. Eur Heart J 1996; 17: 1686-1693.
32. Brutsaert DL, Fransen P, Andries LJ, De Keulenaer GW, Sys SU. Cardiac endothelium and myocardial function. Cardiov Res 1998; 38: 281-290.
33. Brutsaert DL, De Keulenaer GW, Fransen P, Mohan P, Kaluza GL, Andries LJ, Rouleau JL, Sys SU. The cardiac endothelium: functional morphology, development, and physiology. Progress in Cardiovascular Diseases 1996; 39: 239-262.
34. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
35. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Scheider B, Waldḧausl W, Binder BR. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267: 16066-16068.
36. Love MO, McMurray JJV. Endothelin in congestive heart failure. Basic Res Cardiol 1996; 91 (suppl 1): 21-29.
37. Hiroe M, Hirata Y, Fujita N. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol 1991; 68: 1114-1115.
38. McMurray JJ, Ray SG, Abdullah I, Dargie HD, Morton JJ. Plasma endothelin in chronic heart failure. Circulation 1992; 85: 1374-1379.
39. Lerman A, Kubo SH, Tschumperlin LK, Burnett JC Jr. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol 1992; 20: 849-853.
40. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-509.
41. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992; 26: 510-517.
42. Pacher R, Bergler-Klein J, Globits S. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993; 71: 1293-1299.
43. Cacoub P, Dorent R, Nataf P. Plasma endothelin and pulmonary pressures in patients with congestive heart failure. Am Heart J 1993; 126: 1484-1588.
44. Wei C-M, Lerman A, Rodeheffer RJ. Endothelin in human congestive heart failure. Circulation 1994; 89: 1580-1586.
45. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-1579.
46. Pacher R, Stanek B, Hülsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996; 27: 633-641.
47. Levin ER. Mechanisms of disease. Endothelins. N Engl J Med 1995; 333: 356-363.
48. Frelin C, Guedin D. Why are circulating concentrations of endothelin-1 so low? Cardiov Res 1994; 28: 1613-1622.
49. Øie E, Vinge LE, Tønnessen T, Grøgaard HK, Kjekshus H, Christensen G, Smiseth OA, Attramadal H. Transient, isopeptide-spedfic induction of myocardial endothelin-1 mRNA in congestive heart failure in rats. Am J Physiol 1997; 273: H1727-H1736.
50. Tønnessen T, Christensen G, Øie E, Holt E, Kjekshus H, Smiseth OA, Sejersted OM, Attramadal H. Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats. Cardiov Res 1997; 33: 601-610.
51. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathways improves long-term survival in heart failure. Nature 1996; 384: 353-355.
52. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 1996; 93: 1214-1222.
53. Li K, Rouleau JL. Altered responsiveness to endothelin-1 of myocardium from pacing-induced heart failure model in the dog. Cardiovascular Drugs and Therapy 1996; 10: 107-112.
54. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. Circulation 1997; 95: 1918-1929.
55. Colucci WS. Myocardial endothelin. Does it play a role in myocardial failure? Circulation 1996; 93: 1069-1072.
56. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325-415.
57. De Keulenaer GW, Andries LJ, Sys SU, Brutsaert DL. Endothelin-mediated positive inotropic effect induced by reactive oxygen species in isolated cardiac muscle. Circ Res 1995; 76: 878-884.
58. 2+ transient and contractility in ferret myocardium. Circ Res 1992; 71: 631-639.
59. James AF, Xie L, Fujitani Y, Hayashi S, Horie M. Inhibition of cardiac protein kinase A-dependent chloride conductance by endothelin-1. Nature 1994; 370: 297-300.
60. Ono K, Tsujimoto G, Sakamoto A, Eto K, Masaki T, Ozaki Y, Satake M. Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature 1994; 370: 301-304.
61. Shimoyama H, Sabbah HN, Borzak S, Tanimura M, Shevlyagin S, Scicli G, Goldstein S. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation 1996; 94: 779-784.
62. Fraccarollo D, Hu K, Galuppo P, Gaudron P, Ertl G. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction. Possible involvement of myocardial endothelin system in ventricular remodelling. Circulation 1997; 96: 3963-3973.
63. Wada A, Tsutamoto T, Fukai D, Ohnishi M, Maeda K, Hisanaga T, Maeda Y, Matsuda Y, Kinoshita M. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol 1997; 30: 1385-1392.
64. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJV. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996; 94: 2131-2137.
65. Galatius-Jensen S, Wroblewski H, Emmeluth C, Bie P, Haunsø S, Kastrup J. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiov Res 1996; 32: 1148-1154.
66. Di Pasquale P, Valdes L, Albano V, Bucca V, Scalzo S, Pieri D, Maringhini G, Paterna S. Early captopril treatment reduces plasma endothelin concentrations in the acute and subacute phases of myocardial infarction: a pilot study. J Cardiov Pharm 1997; 29: 202-208.
67. Krum H, Gu A, Wilshire-Clement M, Sackner-Bernstein J, Goldsmith R, Medina N, Yushak M, Miller M, Packer M. Changes in plasma endothelin-1 levels reflect clinical response to β-blockade in chronic heart failure. Am Heart J 1996. 131: 337-341.
68. Teerlink JR, Löffler B-M, Hess P, Maire J-P, Clozel M, Clozel J-P. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist RO 47-0203 (bosentan). Circulation 1994; 90: 2510-2518.
69. Seta Y, Shan K, Boskurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Failure 1996; 2: 243-249.
70. Torre-Amione G, Kapadia S, Benedict S, Benedict C, Young J, Mann D. TNFα levels are elevated in SOLVD patients but do not correlate with circulating neurohormones. Circulation 1994; 90 (suppl-I): I-380.
71. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J 1991; 66, 356-358.
72. Han J, Peeper-Woodford S, Drenning D. Circulating TNF and endothelium-derived relaxing factor in severe heart failure: effects of cardiac transplantation. Circulation 1994; 90(suppl-I): I-38.
73. Katz SD, Rao R, Berman JW, Schwartz M, Demopoulos L, Bijou R, LeJemtel TH. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994; 90: 12-16.
74. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulation cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994; 72: 561-566.
75. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure. Circulation 1995; 92: 1479-1486.
76. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995; 92: 1487-1493.
77. Levin B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in congestive heart failure. N Engl J Med 190; 323: 236-241.
78. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor α in severe congestive cardiac failure. Br heart J 1993; 70: 141-143.
79. Ferrari R, Bachetti T, Confortini R. Tumor necrosis factor soluble receptors in patients with various degrees of chronic heart failure. Circulation 1995; 92: 1479-1486.
80. α. J. Am. Coll. Cardiol. 1993; 22: 1897-1901
81. Hegewisch S, Weh HJ, Hossfed DK. TNF-induced cardiomyopathy. Lancet 1990; 2: 294-295.
82. Torre-Amione G, Kapadia S, Lee J. Tumor necrosis factor-α and tumor necrosis receptors in the failing human heart. Circulation 1996; 93: 704-711.
83. Habit FM, Springal DR, Davies GJ, Oakley CM, Yacoub MN, Polak JM. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996; 347: 1151-1154.
84. Hatwood GA, Tsao PS, Von Der Leyen HE. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996; 93: 1087-1094.
85. Yoshizumi M, Perrella MA, Burnett JCJ, Lee M-E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-209.
86. Flores EA, Bistrian BR, Pomposelli JJ, Dinarello CA, Blackburn GL, Istfan NW. Infusion of tumour necrosis factor/cachectin produces muscle catabolism in the rat: asynergistic effect with interleukin-A. J Clin Invest 1989; 83: 1614-1622.
87. Thaik CM, Calderone A, Takahashi N, Collucci WS. Interleukin 1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995; 96: 1093-1099.
88. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest 1995; 95: 677-685.
89. Klefstrom J, Koskinen PJ, Saksela E, Jaattela M, Bravo R, Alitalo K. A subset of immediate early mRNAs induced by tumor necrosis factor-alpha during cellular cytotoxic and non-cytotoxic responses. Int J Cancer 1993; 55: 655-659.
90. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation 1995; 92: 1379-1382.
91. De Keulenaer GW, Chappell DC, Ishizaka N, Nerem RN, Alexander RW, Griendling KK. Oscillatory and steady laminar shear stress differentially affect human endothelial redox state. Role of a superoxide-producing NADH oxidase. Circ Res 1998; 82: 1094-1101.
92. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992; 70: 593-599.
93. Stoian I, Oros A, Moldoveanu E. Apoptosis and free radicals. Biochem & Mol Med 1996; 59: 93-97.
94. De Keulenaer GW, Ushio-Fukai M, Ishizaka N, Alexander RW, Griendling KK. TNFalpha activates a p22phox-based NADH oxidase in vascular smooth muscle cells. Biochem J 1998; 329: 653-657.
95. Marui N, Offerman M, Swerlick R, Kunsch C, Roxen CA, Ahmad M, Alexander RW, Medford RM. Vascular cell-adhesion molecule-1 (VCAM-1) gene-transcription and expression are regulated through an antioxidant sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92: 1866-1874.
96. Rao GN. Hydrogen peroxide induces complex formation of SHC-Grb2-SOS with receptor tyrosine kinase and activates ras and extracellular signal-regulated protein kinases group of mitogen activated protein kinases. Oncogene 1996; 13: 713-719.
97. Torre-Amione G, Kapadia S, Lee J, Durand J-B, Bies RD, Young JB, Mann DL. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-711.
98. Bryant D. Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thompson M, Giroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α. Circulation 1998; 97: 1375-1381.
99. Sasayama S, Matsumori A. Vesnarinone: a potential cytokine inhibitor. J Card Failure 1996; 2: 251-257.
100. Matsumori A, Ono K, Nishio R, Igata H, Shioi T, Matsui S, Furukawa Y, Iwasaki A, Nose Y, Sasayama S. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 1997; 96: 1501-1506.
101. Ruffolo RR Jr, Feuerstein GZ. Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure. European Heart Journal 1998; 19(suppl B): B19-24.
102. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. Circulation 1997; 96: 1386-1389.
103. Mohler ER, Sorensen LC, Ghali JK, Schocken DD, Willis PW, Bowers JA, Cropp AB, Pressler ML. Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. J Am Coll Cardiol 1997; 30: 35-41.